Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events). Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors
- Exhibit 99.1 contains the substantive investor materials and should be reviewed for pipeline, clinical, or commercial updates
Item EX-99.1 · Exhibit EX-99.1
- 3Q26 revenue ~$382M, up ~80% YoY and ~22% QoQ, demonstrating accelerating Amtagvi commercial adoption
- Full-year 2026 revenue guidance $410M-$420M, midpoint up $55M or ~15% versus prior guidance of $350M-$370M
- Cash ~$382M with runway well into 2029, reducing near-term financing pressure while pipeline programs advance
- NSCLC data showed 24.6% ORR overall and 59% ORR in biomarker-enriched patients, supporting planned 2027 sBLA submission
- Commercial infrastructure exceeded 100 ATCs across the U.S., Canada and Australia, with 5K+ annual manufacturing capacity supporting expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.